OnceDaily

FDA Approves Once-Daily Rheumatoid Arthritis Oral Drug, Xeljanz XR, by Pfizer
Pfizer, Inc., recently announced that the U.S. Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release 11 mg tablets as a once-daily treatment of patients with moderate to severe rheumatoid arthritis (RA) who ... [...]
6
Like
Save
Short on label expansions, Pfizer nabs FDA OK for new, once-daily Xeljanz
But in the meantime, it's rolling out a new extended-release formula for the disease it's already approved to treat. Wednesday, the FDA approved an extended-release formulation of Xeljanz, a second-line, oral rheumatoid arthritis therapy. Patients can ... [...]
4
Like
Save
Once-Daily Rheumatoid Arthritis Treatment Submitted for Review
"Lilly's collaboration with Incyte has produced a rigorous phase 3 program and, if approved, the potential of a promising new treatment option for people with RA [rheumatoid arthritis]," said David Ricks, president of Lilly Bio-Medicines, in a press ... [...]
4
Like
Save
Lilly seeks US FDA approval for oral once-daily RA drug, baricitinib
... biopharmaceutical company, announced that Lilly has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid ... [...]
5
Like
Save
New Drug Application Submitted for Once-Daily Baricitinib for RA Patients
A new drug application (NDA) has been submitted to the FDA for the approval of oral once-daily baricitinib (Eli Lilly/Incite Corporation) for the treatment of moderately to severely active rheumatoid arthritis (RA). Baricitinib is the only once-daily ... [...]
7
Like
Save